MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Organization & Developments: Regeneron
Parents
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Children
*Dupixent (dupilumab)
*Eylea/Eylea HD (aflibercept)
*Regeneron (NASDAQ:REGN) is focused on drug discovery methods rather than merely compounds
*Regeneron Genetics Center _Explore the mysteries hidden in the world’s largest genomic database
*Regeneron Ireland
*Regeneron's Velocisuite
*Treatment for age-related macular degeneration, aflibercept (also known as VEGF Trap-Eye), Regeneron Pharmaceuticals
*U.S. based-Regeneron Pharmaceuticals Inc and Germany's Bayer AG said they would co-develop an antibody for use in combination with Eylea, their treatment for a form of age-related blindness - macular degeneration (wet AMD)
2017: HHS_Ebola Therapeutics
2017: Reassessing Regeneron - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
2017: Regeneron Touts Success in Big Asthma Drug Study, Plans FDA Filing
2017: Regeneron: High Growth, High Valuation - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
2017: Why Regeneron May Have Lots Of Growth Ahead - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
2018: Regeneron: The Chart Obscures The Progress - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
2019: How Regeneron Can Take Its Sad Song And Make It (Much) Better_seekingalpha.com
2019: Regeneron Rebounds Again: A Progress Report_seekingalpha.com
2019: Regeneron: Regenerating As Usual_seekingalpha.com
2020: DoctoRx: Regeneron: Cancer, COVID, And More Could Be Breaking Its Way
2020: First Ebola therapy approved by the FDA
2020: Regeneron antibody cocktail given to Trump cleared for general use
2020: Regeneron kicks off prevention trial for COVID-19 antibody cocktail
2020: Regeneron Posts Positive Data For Covid-19 Treatment; Lung Cancer Drug Advances
2020: Regeneron: Favorable Performance Of Current Product Portfolio, Impressive Pipeline Bode Well For Growth Over The Next Decade
2022: Hospital and Drugmaker Move to Build Vast Database of New Yorkers’ DNA_“‘Mount Sinai Million Health Discoveries Program.”_www.nytimes.com
2022: Mount Sinai, Regeneron unveil plans to sequence and study 1M patients' genomes
2022: MyCode: DNA sequencing for better health outcomes _Geisinger
2022: Regeneron Pharmaceuticals (REGN) Investor Presentation- Slideshow_seekingalpha.com
2022: Regeneron: Fortune Seems To Favor This Bold, Innovative Pharma_seekingalpha.com
2022: Regeneron: Q3 Results Show Eylea's Strength Despite Vabysmo Launch_ seekingalpha.com
2022: Regeneron: Stock Priced Too High To Buy, But Keep One Eye On This Pharma_ seekingalpha.com
2023: New effort aims to build an African ancestry biobank_ axios
2023: Regeneron Gains After Eye-Drug Patent Victory Over Viatris
2023: Regeneron: Analysis Of Vabysmo's Impact On Eylea Franchise_ seekingalpha.com
2023: Regeneron: Eylea Growth Scare And Many Other Developments_ seekingalpha
2024: AACR: Regeneron's multiple myeloma drug shows staying power, just after FDA accepts it for quick review_fiercebiotech
2024: Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors_seekingalpha.com
2024: Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight
2024: Regeneron Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
2024: Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2023
2024: Regeneron Stock: Valuation Now Demands More Growth
2024: Regeneron Ventures Launches with $500 Million Commitment to Fuel Promising Biotechnology Innovation
2024: Regeneron: Investors In Panic Mode On Increased Eylea Fears
2024: Regeneron: The Biotech Stock To Buy Now
2024: Regeneron's Push Into Obesity, Q4 2023 Earnings Review
2024: Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
2024: The $100 billion club gets a shakeup, driven by biotech’s new blue-chip names_ Vertex & Regeneron-surpass-100b-market-caps
2024: Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade)_ seekingalpha.com
2025: #4. Dupixent (dupilumab)1 Sanofi and Regeneron Pharmaceuticals 2024 Sales: $15.125 billion (€13.072 billion) 2023 Sales: $12.398 billion (€10.715 billion) % Change: +22.0%
2025: Regeneron Buys 23andMe in Bankruptcy Auction
2025: Regeneron Is Playing Defense With Capital Allocation
2025: Regeneron Pharmaceuticals declares its first-ever dividend of $0.88, announces $3.0B buyback_seekingalpha.com
2025: Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?
2025: Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings
2025: Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025
2025: Regeneron wins FDA accelerated nod for multiple myeloma therapy
2025: Regeneron: Drug Pricing Woes Notwithstanding, Due For A Major Comeback
2025: Regeneron: Phase III Success In Skin Cancer For Libtayo
2025: Regeneron: Potential Entrant To Weight Loss Market
2025: Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025_ seekingalpha.com
2025: Regeneron's SWOT analysis: biotech giant's stock faces eylea challenges, pipeline promise
2025: Why Regeneron's Price May Soon Break Out_seekingalpha.com
2026: 44th Annual J.P. Morgan Healthcare Conference (NASDAQ:REGN) 2026-01-12
2026: Regeneron at J.P. Morgan Healthcare Conference (January 2026) — Summary
Regeneron Ventures
Jumps
*Key People: Regeneron
Finance & Acquisitions: Regeneron
Organization & Developments: Regeneron (Archives 2014-2016)